Mild cognitive disturbance: definition, diagnosis, prognosis, and therapy

被引:21
作者
Kurz, A
Diehl, J
Riemenschneider, M
Perneczky, R
Lautenschlager, N
机构
[1] Tech Univ Munich, Klin Psychiat & Psychotherapie, D-81675 Munich, Germany
[2] Univ Western Australia, Sch Psychiat & Clin Neurosci, Perth, WA 6009, Australia
来源
NERVENARZT | 2004年 / 75卷 / 01期
关键词
mild cognitive impairment; Alzheimer's disease; dementia; diagnosis; treatment;
D O I
10.1007/s00115-003-1568-4
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The syndrome of mild cognitive impairment (MCI) is heterogeneous in terms of aetiology, psychopathology, and prognosis. It is characterised by cognitive deterioration significantly exceeding the decline attributable to aging but not reaching the severity of dementia. The prevalence of MCI is estimated to be 17% in the population over 65 years old. At neuropathological examination,a large proportion of patients with mild cognitive impairment, particularly of the amnestic type, show typical features of Alzheimer's disease. The former progresses to dementia at an annual rate of 10% to 15%. In some cases, however,there is stable impairment or remission. The neurodegenerative process of Alzheimer's disease can be demonstrated in at least some patients using volumetric magnetic resonance imaging, 18-FDG positron emission tomography, or biochemical markers in the cerebrospinal fluid. It is not yet known whether patients with mild cognitive impairment or at least those with pre-dementia Alzheimer's disease can benefit from currently available symptomatic treatments. Patients with early-stage Alzheimer's are an important target group for treatment interventions aiming at slowing the neurodegenerative process.
引用
收藏
页码:6 / +
页数:10
相关论文
共 84 条
[1]   Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment [J].
Andreasen, N ;
Minthon, L ;
Vanmechelen, E ;
Vanderstichele, H ;
Davidsson, P ;
Winblad, B ;
Blennow, K .
NEUROSCIENCE LETTERS, 1999, 273 (01) :5-8
[2]   Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease:: a community based follow up study [J].
Andreasen, N ;
Vanmechelen, E ;
Van de Voorde, A ;
Davidsson, P ;
Hesse, C ;
Tarvonen, S ;
Räihä, I ;
Sourander, L ;
Winblad, B ;
Blennow, K .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1998, 64 (03) :298-305
[3]   Cerebrospinal fluid levels of total-tau, phospho-tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment [J].
Andreasen, N ;
Vanmechelen, E ;
Vanderstichele, H ;
Davidsson, P ;
Blennow, K .
ACTA NEUROLOGICA SCANDINAVICA, 2003, 107 :47-51
[4]   Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease [J].
Arnáiz, E ;
Almkvist, O .
ACTA NEUROLOGICA SCANDINAVICA, 2003, 107 :34-41
[5]   A PREVALENCE STUDY OF AGE-ASSOCIATED MEMORY IMPAIRMENT [J].
BARKER, A ;
JONES, R ;
JENNISON, C .
BRITISH JOURNAL OF PSYCHIATRY, 1995, 167 :642-648
[6]   Progression to dementia in patients with isolated memory loss [J].
Bowen, J ;
Teri, L ;
Kukull, W ;
McCormick, W ;
McCurry, SM ;
Larson, EB .
LANCET, 1997, 349 (9054) :763-765
[7]   Screening for dementia of the Alzheimer type in the community: The utility of the clock drawing test [J].
Cahn, DA ;
Salmon, DP ;
Monsch, AU ;
Butters, N ;
Wiederholt, WC ;
CoreyBloom, J ;
BarrettConnor, E .
ARCHIVES OF CLINICAL NEUROPSYCHOLOGY, 1996, 11 (06) :529-539
[8]   PREVALENCE OF AGE-ASSOCIATED MEMORY IMPAIRMENT AND DEMENTIA IN A RURAL-COMMUNITY [J].
CORIA, F ;
DECASO, JAG ;
MINGUEZ, L ;
RODRIGUEZARTALEJO, F ;
CLAVERIA, LE .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1993, 56 (09) :973-976
[9]  
CROOK TH, 1993, TREATMENT CARE OLD A, pS95
[10]   Age-Associated Memory Impairment: Proposed Diagnostic Criteria and Measures of Clinical Change - Report of a National Institute of Mental Health Work Group [J].
Crook, Thomas ;
Bartus, Raymond T. ;
Ferris, Steven H. ;
Whitehouse, Peter ;
Cohen, Gene D. ;
Gershon, Samuel .
DEVELOPMENTAL NEUROPSYCHOLOGY, 1986, 2 (04) :261-276